Literature DB >> 26371309

Creation of a histone deacetylase 6 inhibitor and its biological effects [corrected].

Ju-Hee Lee1, Yuanshan Yao2, Adaickapillai Mahendran2, Lang Ngo1, Gisela Venta-Perez1, Megan L Choy1, Ronald Breslow3, Paul A Marks4.   

Abstract

We report the development of a potent, selective histone deacetylase 6 (HDAC6) inhibitor. This HDAC6 inhibitor blocks growth of normal and transformed cells but does not induce death of normal cells. The HDAC6 inhibitor alone is as effective as paclitaxel in anticancer activity in tumor-bearing mice.

Entities:  

Keywords:  HDAC; cancer; tubulin

Mesh：

Substances：

Year:  2015        PMID： 26371309      PMCID： PMC4593111          DOI： 10.1073/pnas.1515882112

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  13 in total

1.  A novel class of small molecule inhibitors of HDAC6.

Authors:  Elizabeth S Inks; Benjamin J Josey; Sean R Jesinkey; C James Chou
Journal:  ACS Chem Biol       Date:  2011-11-11       Impact factor: 5.100

2.  Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Authors:  Loredana Santo; Teru Hideshima; Andrew L Kung; Jen-Chieh Tseng; David Tamang; Min Yang; Matthew Jarpe; John H van Duzer; Ralph Mazitschek; Walter C Ogier; Diana Cirstea; Scott Rodig; Homare Eda; Tyler Scullen; Miriam Canavese; James Bradner; Kenneth C Anderson; Simon S Jones; Noopur Raje
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

3.  Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents.

Authors:  Mandana Namdar; Gisela Perez; Lang Ngo; Paul A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-29       Impact factor: 11.205

4.  HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation.

Authors:  R B Parmigiani; W S Xu; G Venta-Perez; H Erdjument-Bromage; M Yaneva; P Tempst; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-07       Impact factor: 11.205

5.  Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

Authors:  J-H Lee; M L Choy; L Ngo; S S Foster; Paul A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

Review 6.  Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions.

Authors:  Paul A Marks
Journal:  Biochim Biophys Acta       Date:  2010-06-08

Review 7.  Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug.

Authors:  Paul A Marks; Ronald Breslow
Journal:  Nat Biotechnol       Date:  2007-01       Impact factor: 54.908

8.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.

Authors:  V M Richon; S Emiliani; E Verdin; Y Webb; R Breslow; R A Rifkind; P A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

9.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Authors:  L M Butler; D B Agus; H I Scher; B Higgins; A Rose; C Cordon-Cardo; H T Thaler; R A Rifkind; P A Marks; V M Richon
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

10.  HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor.

Authors:  Jeffrey J Kovacs; Patrick J M Murphy; Stéphanie Gaillard; Xuan Zhao; June-Tai Wu; Christopher V Nicchitta; Minoru Yoshida; David O Toft; William B Pratt; Tso-Pang Yao
Journal:  Mol Cell       Date:  2005-05-27       Impact factor: 17.970
View more
  10 in total

1.  Entropy as a Driver of Selectivity for Inhibitor Binding to Histone Deacetylase 6.

Authors:  Nicholas J Porter; Florence F Wagner; David W Christianson
Journal:  Biochemistry       Date:  2018-05-18       Impact factor: 3.162

2.  Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity.

Authors:  Nicholas J Porter; Jeremy D Osko; Daniela Diedrich; Thomas Kurz; Jacob M Hooker; Finn K Hansen; David W Christianson
Journal:  J Med Chem       Date:  2018-08-17       Impact factor: 7.446

3.  Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.

Authors:  Nicholas J Porter; Adaickapillai Mahendran; Ronald Breslow; David W Christianson
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-04       Impact factor: 11.205

4.  Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.

Authors:  Teru Hideshima; Jun Qi; Ronald M Paranal; Weiping Tang; Edward Greenberg; Nathan West; Meaghan E Colling; Guillermina Estiu; Ralph Mazitschek; Jennifer A Perry; Hiroto Ohguchi; Francesca Cottini; Naoya Mimura; Güllü Görgün; Yu-Tzu Tai; Paul G Richardson; Ruben D Carrasco; Olaf Wiest; Stuart L Schreiber; Kenneth C Anderson; James E Bradner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-31       Impact factor: 11.205

Review 5.  Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.

Authors:  Jeremy D Osko; David W Christianson
Journal:  Bioorg Med Chem Lett       Date:  2020-02-11       Impact factor: 2.823

6.  Binding Free Energy (BFE) Calculations and Quantitative Structure-Activity Relationship (QSAR) Analysis of Schistosoma mansoni Histone Deacetylase 8 (smHDAC8) Inhibitors.

Authors:  Conrad V Simoben; Ehab Ghazy; Patrik Zeyen; Salma Darwish; Matthias Schmidt; Christophe Romier; Dina Robaa; Wolfgang Sippl
Journal:  Molecules       Date:  2021-04-28       Impact factor: 4.411

7.  Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.

Authors:  Sara Ota; Zi-Qiang Zhou; Peter J Hurlin
Journal:  Oncotarget       Date:  2017-12-01

8.  Combinatorial In Silico Strategy towards Identifying Potential Hotspots during Inhibition of Structurally Identical HDAC1 and HDAC2 Enzymes for Effective Chemotherapy against Neurological Disorders.

Authors:  Shabir Ahmad Ganai; Ehsaan Abdullah; Romana Rashid; Mohammad Altaf
Journal:  Front Mol Neurosci       Date:  2017-11-09       Impact factor: 5.639

Review 9.  HDAC6-an Emerging Target Against Chronic Myeloid Leukemia?

Authors:  Hélène Losson; Michael Schnekenburger; Mario Dicato; Marc Diederich
Journal:  Cancers (Basel)       Date:  2020-01-29       Impact factor: 6.639

Review 10.  Next-generation of selective histone deacetylase inhibitors.

Authors:  Feifei Yang; Na Zhao; Di Ge; Yihua Chen
Journal:  RSC Adv       Date:  2019-06-24       Impact factor: 4.036
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.